A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
Sponsor
Intarcia Therapeutics (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT01455883
Collaborator
(none)
0
1
2
16.9
0
Study Details
Study Description
Brief Summary
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Study Start Date
:
Feb 1, 2013
Anticipated Primary Completion Date
:
Jul 1, 2014
Anticipated Study Completion Date
:
Jul 1, 2014
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: ITCA 650 60 mcg/day ITCA 650 is exenatide in DUROS |
Drug: ITCA 650 60 mcg/day
exenatide in DUROS
|
Active Comparator: glimepiride glimepiride up-titrated to 8 mg/day over first 13 weeks |
Drug: glimepiride
oral glimepiride does-escalated,if tolerated, to 8 mg/day
|
Outcome Measures
Primary Outcome Measures
- Change in HbA1c [52 weeks]
52-Week Treatment Period
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
HbA1c between 7.5% - 10.5%
-
on metformin monotherapy
-
BMI between 25 & 45 kg/m2
Exclusion Criteria:
-
on thiazolidinedione, sulfonylureas, DPP-4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
-
history of pancreatitis
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Intarcia Therapeutics, Inc | Hayward | California | United States | 94545 |
Sponsors and Collaborators
- Intarcia Therapeutics
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Intarcia Therapeutics
ClinicalTrials.gov Identifier:
NCT01455883
Other Study ID Numbers:
- ITCA 650-CLP-106
First Posted:
Oct 20, 2011
Last Update Posted:
Dec 25, 2012
Last Verified:
Dec 1, 2012